Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
May 10, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 10, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
March 30, 2023 16:05 ET
|
Adial Pharmaceuticals, Inc
Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0...
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
March 21, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
March 08, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
March 06, 2023 16:19 ET
|
Adial Pharmaceuticals, Inc
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authoritiesAdial in discussions...
Adial Pharmaceuticals Schedules Business Update Conference Call
March 02, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
February 27, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
February 24, 2023 07:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
February 21, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial...
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
February 01, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley ...